Enviomycin

DB08993ExperimentalSmall molecule

Cyclic basic peptide related to viomycin. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

Formula / weight: C₂₅H₄₃N₁₃O₁₀ · 685.69 g/mol (avg)
Also known as: Tuberactinomycin N

Resolves to

Compound

UNIIXU299C23A2CAS33103-22-9ChEMBLCHEMBL2146142PubChem20055267KEGGD07897

Clinical / RWD

ATCJ04AB06

Structure

InChIKeyHPWIIERXAFODPP-GHBBWTPBSA-NSMILES

[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC1=O)NC(=O)C[C@@H](N)[C@H](O)CCN)=C\NC(N)=O

What you can answer from here — as of August 30, 2026

58Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 9 drug categories

Which companies are running trials of Enviomycin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account